a year ago

CN Bio Raises $21 Million to Advance Organ-on-Chip Technology

  • CN Bio, a Cambridge-based drug discovery company, has secured $21 million (£17 million) in Series B funding to advance its organ-on-chip (OOC) technology

  • The company's OOC technology involves growing engineered or natural tissues inside chips to mimic human physiology, providing a more ethical and accurate alternative to animal testing for drug development

  • The funding round was led by Bayland Capital, with participation from founding shareholder CN Innovations Holdings

  • CN Bio plans to use the funds to expand its research and development in the OOC drug discovery space.

      • ProblemTechnology

      "Currently, animal testing is a necessary step in the drug discovery process, which can be time-consuming, expensive, and raises ethical concerns."

      Solution

      "CN Bio's organ-on-chip technology enables the development of in vitro organ models that can accurately mimic human physiology, eliminating the need for animal testing."

      Covered on